Hematologic issues in COVID-19

1. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020.Apr 9. doi: 10.1111/jth.14830. [Epub ahead of print]
2. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18:786-7.
3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7.
4. Rezaie S. COVID-19: Thrombosis and Hemoglobin 2020 [cited 2020 April 9]. Available from: https://rebelem.com/covid-19-thrombosis-and-hemoglobin/.
5. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. Apr 10:S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013. Epub ahead of print. PMID: 32291094; PMCID: PMC7146714.
6. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020. Apr 17. doi: 10.1111/jth.14850. [Epub ahead of print]
7. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020. doi: https://doi.org/10.1016/j.kint.2020.04.003.
8. Hunt BR, A. McClintock, C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19 International Society on Thrombosis and Haemostasis; 2020 [cited 2020 March 25]. Available from: https://thrombosisuk.org/covid-19-thrombosis.php.
9. Tang NB, H. Chen, X. Gong, J. Li, D. Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. May;18:1094-9. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
10. Barrett CD, Moore HB, Yaffe MB, Moore EE. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment. J Thromb Haemost. 2020. Apr 17. doi: 10.1111/jth.14860. [Epub ahead of print]
11. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020. Apr 15. doi: 10.1111/jth.14844. [Epub ahead of print]
12. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020. Apr 15. pii: S1931-5244(20)30070-0. doi: 10.1016/j.trsl.2020.04.007. [Epub ahead of print]
13. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. Zhonghua Bing Li Xue Za Zhi. 2020;49(0):E009.
14. Cuker A, Peyvandi F. Coronavirus disease 2019 (COVID-19): Hypercoagulability 2020 [cited 2020 April 29]. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-hypercoagulability.
15. Kreuziger LL, A. Garcia, D. Cuker, A. Cushman, M. Connors, J. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions American Society of Hematology; 2020 [cited 2020 April 17]. Version 2.1:[Available from: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation.
16. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J Am Coll Cardiol. 2020. Apr 15:S0735-1097(20)35008-7. doi: 10.1016/j.jacc.2020.04.031. Epub ahead of print. PMID: 32311448; PMCID: PMC7164881.
17. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects?Thromb Haemost. 2017 Feb 28;117:437-44. doi: 10.1160/TH16-08-0620. Epub 2016 Dec 15
18. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. DOACs and 'newer' haemophilia therapies in COVID-19. J Thromb Haemost. 2020. Apr 13. doi: 10.1111/jth.14841. [Epub ahead of print]
19. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.